Investigational Antifungal Agents for Invasive Mycoses: A Clinical Perspective.

Abstract

Treatment of invasive fungal infections (IFIs) remains challenging, because of the limitations of the current antifungal agents (ie, mode of administration, toxicity, and drug-drug interactions) and the emergence of resistant fungal pathogens. Therefore, there is an urgent need to expand our antifungal armamentarium. Several compounds are reaching the stage of phase II or III clinical assessment. These include new drugs within the existing antifungal classes or displaying similar mechanism of activity with improved pharmacologic properties (rezafungin and ibrexafungerp) or first-in-class drugs with novel mechanisms of action (olorofim and fosmanogepix). Although critical information regarding the performance of these agents in heavily immunosuppressed patients is pending, they may provide useful additions to current therapies in some clinical scenarios, including IFIs caused by azole-resistant Aspergillus or multiresistant fungal pathogens (eg, Candida auris, Lomentospora prolificans). However, their limited activity against Mucorales and some other opportunistic molds (eg, some Fusarium spp.) persists as a major unmet need.

• Authors: Frederic Lamoth, Russell E Lewis, Dimitrios P Kontoyiannis
• Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (Clin Infect Dis) Vol. 75 Issue 3 Pg. 534-544 (08 31 2022) ISSN: 1537-6591 [Electronic] United States
• PMID: 34986246 (Publication Type: Journal Article)
• Copyright: © The Author(s) 2022. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: [email protected].

Chemical References

• Antifungal Agents
• Azoles

Topics

• Antifungal Agents (pharmacology, therapeutic use)
• Aspergillus
• Azoles (pharmacology, therapeutic use)
• Drug Resistance, Fungal
• Fungi
• Humans
• Invasive Fungal Infections (drug therapy)
• Microbial Sensitivity Tests